Sign up
Pharma Capital

Dimerix appoints Kathy Harrison inaugural full time CEO

Dimerix if focused on clinical trials for Chronic Kidney Disease.
dimerix-CE-Kathy-Harrisson-757.png
Kathy Harrison, chief executive officer, Dimerix

Dimerix Ltd (ASX:DXB) has promoted Kathy Harrison to the inaugural full time chief executive officer of the company.

In recognition of Harrison's work, 36,598,968 options (2% of issued capital) have been offered to align her long term incentive with that of shareholders.

In other moves, Dr James Williams who is a co-founder of the company and current executive chairman, will transition to non-executive chairman.

Dr Williams commented:

"In the time since her appointment, Kathy has clearly demonstrated her commitment as Dimerix’s CEO and ability in the role.

"The Dimerix board is fully committed to supporting Kathy as she leads and implements the company’s commercialisation strategy for DMX-200."

Kathy Harrison discusses outcome of DMX-200 trial

Watch video now

Importance of Phase 2a results

The importance of Dimerix's Phase 2a results is that the trial meets the primary safety endpoint and demonstrates encouraging efficacy in a clinically meaningful number of patients.

- 25% of patients achieved a greater than 50% reduction in proteinuria, beyond that achieved with the highest dosage of current standard of care therapy; and

- 45% of patients granted ability to continue ongoing treatment under Special Access Scheme upon recommendation of their advising physician, confirming confidence in the treatment.

The clinically meaningful reductions in proteinuria are highly encouraging and support the rationale behind the program.

Given this is a “hard to treat” patient group, Dimerix now have a very strong indication that the treatment is having a significant impact in slowing the progression of Chronic Kidney Disease.



Register here to be notified of future DXB Company articles
View full DXB profile

Dimerix Ltd Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.